Clinical trial
Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis
NCT03138525 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 20, 2017
- Completion date
- December 20, 2019
- Enrollment
- 161 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy, multiple sclerosis